Diagnostic Accuracy of DNA Methylation Markers for Detecting Cervical Precancer and Cervical Cancer: A Systematic Review and Meta-analysis
学术急诊医学档案,
卷 14 编号 1 (2026),
1 十月 2025
,
第 e37 页
https://doi.org/10.22037/aaem.v14i1.3062
摘要
Background: DNA methylation markers have been proposed as molecular triage tools for detecting cervical precancer and cancer, particularly among HPV-positive women. However, diagnostic performance varies across markers, assays, specimens, and clinical settings. This study aimed to evaluate the marker-specific diagnostic accuracy of DNA methylation markers and methylation panels for detecting CIN2+ and CIN3+ in cervical cancer screening, triage, and related diagnostic contexts. Methods: This systematic review and diagnostic test accuracy meta-analysis was reported according to PRISMA-DTA. Marker-specific analyses were performed separately by endpoint to avoid double counting. Pooled sensitivity, specificity, diagnostic odds ratio, clinical utility estimates, risk of bias, publication bias, and certainty of evidence were assessed using diagnostic test accuracy methods, QUADAS-2, Deeks' test, and GRADE-DTA. Results: The broad main diagnostic meta-analysis included 74 eligible studies, contributing 260 diagnostic test accuracy comparisons across 130 marker-endpoint-sample analyses. A strict sensitivity dataset included 164 comparisons from 51 studies. Seven marker analyses were available for CIN2+ and seven for CIN3+. Diagnostic performance varied by marker and endpoint. For CIN2+, S5 EPB41L3 plus HPV16/18/31/33 methylation showed the highest sensitivity but lower specificity, whereas PAX1, JAM3, SOX1, PAX1/JAM3, and Six-gene/GynTect showed higher specificity. For CIN3+, S5 showed the highest sensitivity, while PAX1/JAM3, JAM3, SOX1, PAX1, and Six-gene/GynTect had more balanced performance. Deeks' test did not show strong evidence of publication bias for most analyses, although borderline findings were observed in selected marker-endpoint analyses. GRADE-DTA certainty was low or very low across marker-endpoint analyses. Conclusions: DNA methylation markers showed heterogeneous diagnostic accuracy for detecting CIN2+ and CIN3+. Some markers demonstrated potentially useful sensitivity- or specificity-oriented profiles, but certainty of evidence was low or very low. Further standardized prospective validation is required before routine clinical implementation.
- cervical cancer
- DNA methylation
- diagnostic test accuracy
- meta-analysis
##submission.howToCite##
参考
1. Bray F, Laversanne M, Sung H, et al. Global cancer sta-tistics 2022: GLOBOCAN estimates of incidence and mor-tality worldwide for 36 cancers in 185 countries. CA Can-cer J Clin. 2024;74(3):229-263.
2. World Health Organization. Global strategy to acceler-ate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization;2020.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
4. Schiffman M, Castle PE, Jeronimo J, et al. Human papil-lomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
5. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical can-cer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532.
6. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Over-view of human papillomavirus-based and other novel op-tions for cervical cancer screening in developed and de-veloping countries. Vaccine. 2008;26 Suppl 10: K29-K41.
7. Arbyn M, Smith SB, Temin S, et al.; Collaboration on Self-Sampling and HPV Testing. Detecting cervical pre-cancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363: k4823.
8. Steenbergen RDM, Snijders PJF, Heideman DAM, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14(6):395-405.
9. Kremer WW, Steenbergen RDM, Heideman DAM, et al. The use of host cell DNA methylation analysis in the de-tection and management of women with advanced cervi-cal intraepithelial neoplasia: a review. BJOG. 2021;128(3):504-514.
10. McInnes MDF, Moher D, Thombs BD, et al.; PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388-396.
11. Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536.
12. Schünemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines:21 part 1. Study design, risk of bias, and indi-rectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129-141.
13. Schünemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines:21 part 2. Test accuracy: inconsistency, im-precision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemi-ol. 2020;122:142-152.
14. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was as-sessed. J Clin Epidemiol. 2005;58(9):882-893.
15. Adcock R, Nedjai B, Lorincz AT, et al. DNA methyla-tion testing with S5 for triage of high-risk HPV positive women. Int J Cancer. 2022;151(7):993-1004.
16. Anisimova M, Jain M, Shcherbakova L, et al. Detection of CADM1, MAL, and PAX1 methylation by ddPCR for tri-age of HPV-positive cervical lesions. Biomedicines. 2025;13(6):1450.
17. Pun PB, Liao YP, Su PH, et al. Triage of high-risk hu-man papillomavirus-positive women by methylated POU4F3. Clin Epigenetics. 2015;7:85.
18. Banila C, Lorincz AT, Scibior-Bentkowska D, et al. Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: a worldwide study. Int J Cancer. 2022;150(2):290-302.
19. Barrett JE, Sundström K, Jones A, et al. The WID-CIN test identifies women with, and at risk of, cervical in-traepithelial neoplasia grade 3 and invasive cervical can-cer. Genome Med. 2022;14:116.
20. Boers A, Wang R, van Leeuwen RW, et al. Discovery of new methylation markers to improve screening for cervi-cal intraepithelial neoplasia grade 2/3. Clin Epigenetics. 2016;8:29.
21. Bonde J, Floore A, Ejegod D, et al. Methylation mark-ers FAM19A4 and miR124-2 as triage strategy for prima-ry human papillomavirus screen positive women: a large European multicenter study. Int J Cancer. 2021;148:396-405.
22. Bowden SJ, Bodinier B, Paraskevaidi M, et al. DNA methylation signatures of cervical pre-invasive and inva-sive disease: an epigenome-wide association study. Int J Cancer. 2025;157(2):305-316.
23. De Strooper LMA, Hesselink AT, Berkhof J, et al. Com-bined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Can-cer Epidemiol Biomarkers Prev. 2014;23:1933-1937.
24. De Strooper LMA, Verhoef VMJ, Berkhof J, et al. Vali-dation of the FAM19A4/miR124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol. 2016;141(2):341-347.
25. De Vuyst H, Franceschi S, Plummer M, et al. Methyla-tion levels of CADM1, MAL, and MIR124-2 in cervical scrapes for triage of HIV-infected, high-risk HPV-positive women in Kenya. J Acquir Immune Defic Syndr. 2015;70(3):311-318.
26. de Waard J, Bhattacharya A, de Boer MT, et al. Identi-fication of a methylation panel as an alternative triage to detect CIN3+ in hrHPV-positive self-samples from the population-based cervical cancer screening programme. Clin Epigenetics. 2023;15(1):103.
27. de Waard J, Bhattacharya A, de Boer MT, et al. Clinical validation of a three-marker methylation panel to detect CIN3+ in vaginal self-samples in the Dutch population-based screening programme. Clin Epigenetics. 2026;18(1):97.
28. Dick S, Kremer WW, De Strooper LMA, et al. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. Gynecol On-col. 2019;154(2):368-373.
29. Dick S, Verhoef L, De Strooper LMA, et al. Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics. 2020;12(18):1569-1578.
30. Dippmann C, Schmitz M, Wunsch K, et al. Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays. Clin Epigenetics. 2020;12(1):171.
31. Bu Q, Luo X, He L, et al. Septin9 DNA methylation as a promising biomarker for cervical cancer. J Obstet Gy-naecol. 2023;43(1):2151356.
32. Chang CC, Huang RL, Liao YP, et al. Concordance anal-ysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical ne-oplasm. BMC Cancer. 2015;15:418.
33. Chang CL, Ho SC, Su YF, et al. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: real-world evidence in Taiwan. Gynecol Oncol. 2021;161(2):429-435.
34. Chen S, Dai H, Hu S, et al. Novel triple-target panels utilizing methylation-sensitive restriction enzyme-based quantitative PCR for detecting advanced cervical pre-cancers and cancers among high-risk HPV-positive wom-en. J Transl Med. 2025;23(1):857.
35. Clarke MA, Gradissimo A, Schiffman M, et al. Human papillomavirus DNA methylation as a biomarker for cer-vical precancer: consistency across 12 genotypes and po-tential impact on management of HPV-positive women. Clin Cancer Res. 2018;24(9):2194-2202.
36. Cook DA, Krajden M, Brentnall AR, et al. Evaluation of a validated methylation triage signature for human papil-lomavirus positive women in the HPV FOCAL cervical cancer screening trial. Int J Cancer. 2019;144(10):2587-2595.
37. Fan X, Tong Z, Mao S, et al. GYPC methylation perfor-mance in detecting cervical (pre)cancer in high-risk HPV-positive women using liquid-based cervical scrapes. In-fect Agents Cancer. 2025;20(1):69.
38. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, et al. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer. 2014;135(6):1425-1432.
39. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, et al. HPV33 DNA methylation measurement improves cer-vical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and EPB41L3 methylation classifier. Cancer Bi-omark. 2015;15(5):669-675.
40. Fei J, Zhai L, Wang J, et al. Evaluating PAX1/JAM3 methylation for triage in HPV 16/18-infected women. Clin Epigenetics. 2024;16(1):190.
41. Gao Y, Zi D, Liang W, et al. PAX1 and SOX1 gene meth-ylation as a detection and triage method for cervical in-traepithelial neoplasia diagnosis. Acta Cytol. 2024;68(2):137-144.
42. Gilham C, Nedjai B, Scibior-Bentkowska D, et al. Long-term prediction by DNA methylation of high-grade cervi-cal intraepithelial neoplasia: results of the ARTISTIC co-hort. Int J Cancer. 2024;155(1):81-92.
43. Gradissimo A, Clarke MA, Xue X, et al. A novel human papillomavirus and host DNA methylation score and de-tection of cervical adenocarcinoma. J Natl Cancer Inst. 2023;115(12):1535-1543.
44. Hansel A, Steinbach D, Greinke C, et al. A promising DNA methylation signature for the triage of high-risk hu-man papillomavirus DNA-positive women. PLoS One. 2014;9(3):e91905.
45. Hernández-López R, Lorincz AT, Torres-Ibarra L, et al. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping. Clin Epigenetics. 2019;11(1):140.
46. Hesselink AT, Heideman DAM, Steenbergen RDM, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res. 2011;17(8):2459-2465.
47. Klischke L, von Ehr J, Kohls F, et al. Performance of a six-methylation-marker assay on self-collected cervical samples: a feasibility study. J Virol Methods. 2021;295:114219.
48. Kong L, Xiao X, Wu H, et al. Triage performance of DNA methylation for women with high-risk human papil-lomavirus infection. Oncologist. 2025;30(3): oyae324.
49. Kremer WW, Van Zummeren M, Novianti PW, et al. Detection of hypermethylated genes as markers for cer-vical screening in women living with HIV. J Int AIDS Soc. 2018;21(8):e25165.
50. Larsson GL, Carlsson J, Helenius G, et al. Molecular triage on HPV-positive samples in a cervical screening setting. PLoS One. 2025;20(10):e0333539.
51. Leeman A, Ebisch RMF, Kasius A, et al. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation. Gynecol Oncol. 2018;151(2):311-318.
52. Li Y, Wang H, Yang J, et al. Triage accuracy of a six-gene methylation detection for high-risk HPV-positive Chinese women. Afr J Reprod Health. 2025;29(7):137-147.
53. Lin C, Zhu C, Xie M, et al. Analysis of the triage value of multigene methylation testing for CIN2+ in hrHPV-positive patients. Infect Agents Cancer. 2025;20(1):22.
54. Liu Y, Chen Y, Xiong J, et al. Performance of DNA methylation analysis in the detection of high-grade cervi-cal intraepithelial neoplasia or worse (CIN3+): a cross-sectional study. Infect Agents Cancer. 2023;18(1):77.
55. Lorincz AT, Brentnall AR, Vasiljevic N, et al. HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnor-mal cervical cytology. Int J Cancer. 2013;133(3):637-644.
56. Lorincz AT, Brentnall AR, Scibior-Bentkowska D, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016;138(11):2745-2751.
57. Luttmer R, De Strooper LMA, Dijkstra MGD, et al. FAM19A4 methylation analysis in self-samples com-pared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br J Cancer. 2016;115(5):579-587.
58. Mirabello L, Schiffman M, Ghosh A, et al. Elevated methylation of HPV16 DNA is associated with the devel-opment of high grade cervical intraepithelial neoplasia. Int J Cancer. 2013;132(6):1412-1422.
59. Molano M, Machalek DA, Tan G, et al. Performance of CADM1, MAL and miR124-2 methylation as triage mark-ers for early detection of cervical cancer in self-collected and clinician-collected samples: an exploratory observa-tional study in Papua New Guinea. BMJ Open. 2024;14(6):e081282.
60. Mortaki A, Douligeris A, Daskalaki MA, et al. The role of HPV genotyping, cytology, and methylation in the tri-age of high-risk HPV-positive patients. Biomedicines. 2025;13(5):1139.
61. Palmieri L, Zamuner FT, Giomo de Lima D, et al. Cer-vicalMethDx: a precision DNA methylation test to identi-fy risk of high-grade intraepithelial lesions in cervical cancer screening algorithms. Cancer Prev Res (Phila). 2025;18(9):531-540.
62. Peng H, Li J, Zhou Q, et al. Enhanced diagnostic accu-racy of high-grade cervical intraepithelial neoplasia in postmenopausal women through PAX1/JAM3 methyla-tion analysis. Int J Cancer. 2026;158(4):1116-1125.
63. Ramírez AT, Sánchez GI, Nedjai B, et al. Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. Int J Cancer. 2021;148(6):1383-1393.
64. Ren Y, Qin F, Shen L, et al. Triage of women with a positive HPV DNA test: evaluating a DNA methylation panel for detecting cervical intraepithelial neoplasia grade 3 and cervical cancer in cervical cytology samples. BMC Cancer. 2025;25(1):1207.
65. Reuter C, Preece M, Banwait R, et al. Consistency of the S5 DNA methylation classifier in formalin-fixed biop-sies versus corresponding exfoliated cells for the detec-tion of pre-cancerous cervical lesions. Cancer Med. 2021;10(8):2668-2679.
66. Rezhake R, Wang Y, Zhao X, et al. Performance of hu-man gene EPB41L3 and HPV 16/18 viral DNA methyla-tion to triage hrHPV-positive women. Vaccines (Basel). 2024;12(1):46.
67. Rezhake R, Abuduxikuer G, Abudurexiti G, et al. Eval-uation of the multiple HPV-based "screen and triage" al-gorithms in real-world settings of rural China. Cancer Biol Med. 2025;22(9):1053-1067.
68. Salta S, Sequeira JP, Amorim-Fernandes B, et al. Meth-ylation-specific droplet digital PCR: testing a novel triage tool for HrHPV-positive women in the cervical cancer screening program of Northern Portugal. MedComm (2020). 2025;6(7):e70203.
69. Schmitz M, Wunsch K, Hoyer H, et al. Performance of a methylation specific real-time PCR assay as a triage test for HPV-positive women. Clin Epigenetics. 2017;9:118.
70. Schmitz M, Eichelkraut K, Schmidt D, et al. Perfor-mance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages. BMC Cancer. 2018;18:1197.
71. Schreiberhuber L, Barrett JE, Wang J, et al. Cervical cancer screening using DNA methylation triage in a real-world population. Nat Med. 2024;30(8):2251-2257.
72. Shang X, Kong L, You Y, et al. Cytologic DNA methyla-tion for managing minimally abnormal cervical cancer screening results. Int J Gynaecol Obstet. 2025;171:405-414.
73. Su H, Jin X, Kong L, et al. The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection. Br J Cancer. 2025;132:1064-1071.
74. Tian Y, Wu NY, Liou YL, et al. Utility of gene methyla-tion analysis, cytological examination, and HPV-16/18 genotyping in triage of high-risk human papilloma virus-positive women. Oncotarget. 2017;8(37):62274-62285.
75. van Leeuwen RW, Oštrbenk A, Poljak M, et al. DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus pos-itive screening cohort. Int J Cancer. 2019;144(4):746-754.
76. Vasiljević N, Scibior-Bentkowska D, Brentnall AR, et al. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical in-traepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol. 2014;132(3):709-714.
77. Verhoef L, Bleeker MCG, Polman N, et al. Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort. Int J Cancer. 2022;150:440-449.
78. Verlaat W, Snijders PJF, Novianti PW, et al. Genome-wide DNA methylation profiling reveals methylation markers associated with 3q gain for detection of cervical precancer and cancer. Clin Cancer Res. 2017;23(14):3813-3822.
79. Verlaat W, Snoek BC, Heideman DAM, et al. Identifica-tion and validation of a 3-gene methylation classifier for HPV-based cervical screening on self-samples. Clin Can-cer Res. 2018;24(14):3456-3464.
80. Vink FJ, Meijer CJLM, Hesselink AT, et al. FAM19A4/miR124-2 methylation testing and HPV16/18 genotyping in HPV-positive women under the age of 30 years. Clin Infect Dis. 2023;76:e827-e834.
81. Wang Y, Chuan J, Zhu B, et al. Evaluation of PAX1/ST6GALNAC5 methylation as a triage test for cervi-cal intraepithelial neoplasia and cervical cancer. Epige-nomics. 2023;15(3):131-145.
82. Wang M, Ma Y, Zhang N, et al. Methylation testing ver-sus cervical cytology for triage of HPV-positive women: a comparative study. Diagn Microbiol Infect Dis. 2025;113:116917.
83. Yang Q, Jiang Y, Liu F, et al. Comparative evaluation of two DNA methylation assays for triage of hrHPV E6/E7 mRNA-positive women. Front Public Health. 2025;13:1723553.
84. Yuan L, Hu Y, Zhou Z, et al. Quantitative methylation analysis to detect cervical (pre)-cancerous lesions in high-risk HPV-positive women. Int J Clin Exp Med. 2017;10(7):10577-10586.
85. Zhai X, Kong T, Yang X, et al. Clinical performance of triage strategies for HPV-positive women in cervical can-cer screening in rural Yunnan China. BMC Cancer. 2026;26(1):57.
86. Zhang R, Li Y, Han Y, et al. PAX1/SOX1 gene methyla-tion as a detection and triage method for triage of high risk HPV-positive women in cervical cancer screening. Gynecol Oncol Rep. 2025;60:101794.
87. Zhang J, Chen J, Feng H, et al. Prospective study on clinical performance of host DNA methylation assay for triage in women who are HPV-positive - 4 provinces, Chi-na, 2018-2021. China CDC Wkly. 2025;7(43):1368-1376.
88. Zhu P, Xiong J, Yuan D, et al. ZNF671 methylation test in cervical scrapings for cervical intraepithelial neo-plasia grade 3 and cervical cancer detection. Cell Rep Med. 2023;4:101143.
89. Dübbel L, Göken-Riebisch A, Knoll K, et al. The DNA methylation marker ZNF671 has prognostic value for progressing cervical intraepithelial neoplasia. Cancers (Basel). 2025;17(19):3095.
90. Clarke MA, Luhn P, Gage JC, et al. Discovery and vali-dation of candidate host DNA methylation markers for detection of cervical precancer and cancer. Int J Cancer. 2017;141(4):701-710.
91. Floore A, Hesselink A, Oštrbenk A, et al. Intra- and in-ter-laboratory agreement of the FAM19A4/mir124-2 methylation test: results from an international study. J Clin Lab Anal. 2019;33:e22854.
92. Hesselink AT, Heideman DAM, Steenbergen RDM, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer. 2014;135(4):880-886.
93. Liu H, Zhou J, Xiao Y, et al. High-throughput targeted sequencing identifies an HPV methylation panel for de-tecting cervical lesion progression. J Med Virol. 2025;97:e70739.
94. Louvanto K, Aro K, Nedjai B, et al. Methylation in pre-dicting progression of untreated high-grade cervical in-traepithelial neoplasia. Clin Infect Dis. 2020;70:2582-2590.
95. Louvanto K, Verhoef L, Pimenoff V, et al. Low methyl-ation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous in-traepithelial lesions. Int J Cancer. 2024;155(9):1549-1557.
96. Kinkorova Lunackova I, Ondic O, Nemcova J, et al. The methylation test is highly sensitive for HPV-associated endocervical adenocarcinoma and could be helpful as a cytological ancillary test in women with a PAP-smear diagnosis of severe glandular lesion (AGC-NEO+). Cytopathology. 2025;36:568-571.
97. Snellenberg S, De Strooper LMA, Hesselink AT, et al. Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC Cancer. 2012;12:551.
98. Vink FJ, Meijer CJLM, Clifford GM, et al. FAM19A4/miR124-2 methylation in invasive cervical cancer: a retrospective cross-sectional worldwide study. Int J Cancer. 2020;147:1215-1221.
99. Wu R, Wei Y, Wu A, et al. Performance of a six-methylation-marker assay in predicting LEEP specimen histology results of cervical HSIL patients: a retrospective study. BMC Cancer. 2025;25(1):340.
100. Zheng Y, Han J, Qu Y, et al. DNA methylation bi-omarkers for cervical cancer risk prediction in HIV-positive Nigerian women. Int J Cancer. 2025;157:1363-1375.
101. Salta S, Lobo J, Magalhães B, et al. DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis. Clin Epigenetics. 2023;15:125.
102. Zhang L, Tan W, Yang H, et al. Detection of host cell gene/HPV DNA methylation markers: a promising triage approach for cervical cancer. Front Oncol. 2022;12:831949.
- 摘要 ##plugins.themes.ojsPlusA.frontend.article.viewed##: 6 ##plugins.themes.ojsPlusA.frontend.article.times##
- pdf (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 4 ##plugins.themes.ojsPlusA.frontend.article.times##
##plugins.themes.ojsPlusA.frontend.article.downloadstatastics##
##plugins.block.makeSubmission.linkLabel##
SJR
COPE
